Altre lingue Barinthus Biotherapeutics plc

Azioni

BRNS

US91864C1071

Mercato chiuso - Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
1,43 ^USD	-0,25%		+5,54%	-61,25%

21/06	I migliori guadagni del mercato premarket	MT
13/06	BARINTHUS BIOTHERAPEUTICS PLC : da Barclays è Buy	ZM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Top Premarket Gainers	21/06
Barinthus Bio to Cut Workforce 25% to Focus on Hepatitis, Celiac Treatments After Positive Data; Shares Rise After Hours	13/06
Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease	12/06
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections	12/06
Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B	06/06
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial	06/06
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B	06/06
Top Premarket Gainers	06/06
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024	22/05
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024	22/05
Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments	13/05
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer	01/05
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer	01/05
Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective June 3, 2024	01/05
Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	18/04
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections	18/04
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	18/04
ADRs Advance; Connect Biopharma Climbs 19%	05/04
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	03/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Barinthus Biotherapeutics plc

Azioni

BRNS

US91864C1071

Altre lingue

Filtri